Anti-SARS-CoV-2 RBD Cocktail Antibody

Supplier: Genscript
Ratings: (No Reviews)

Total Ratings: 0
Avg. Ratings: 0.0 out of 5

A02161-100 A02161-20
77007-594EA 2344.98 USD
77007-594 77007-568
Anti-SARS-CoV-2 RBD Cocktail Antibody
Antibodies
SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) is a positive-sense single-stranded RNA virus. It caused coronavirus disease 2019 (COVID-19). The B.1.1.529 variant was first reported to WHO from South Africa on 24 November 2021. WHO has designated B.1.1.529 as a VOC, named Omicron. SARS-CoV-2 contains glycosylated spike (S) protein, which is composed of S1 subunit and S2 subunit. The S1 contains a receptor-binding domain (RBD) that can bind to ACE2 receptor on target cells. Neutralizing antibodies against SARS-CoV-2 can block the interaction between SARS-CoV-2 RBD and ACE2. The blocking ability of SARS-CoV-2 neutralizing antibodies is affected by the quantity.This standard product is intended for the calibration of SARS-CoV-2 Omicron neutralizing antibodies. It can be used in the assessment and development of assays for the detection and quantitation of SARS-CoV-2 Omicron neutralizing antibodies. The neutralizing antibody standard binds to multiple neutralizing epitopes in the receptor-binding domain.

  • High specificity
  • High affinity
  • High stability

Genscript offers site-specific neutralizing antibodies, neutralizing antibody standards, and control antibodies.

Type:
Antigen: SARS-CoV-2 RBD
Clonality: Cocktail
Clone:
Conjugation:
Epitope:
Host:
Isotype: IgG
Reactivity:
Order Now

Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Learn more About VWR